Novavax expects COVID vaccine targeting Omicron in fourth quarter

[July 02, 2022] 

(Reuters) - Novavax Inc said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates development of shots to protect against the BA.4 and BA.5 subvariants.

The U.S. FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.

Novavax expects additional preclinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.

The company's vaccine, based on an earlier strain of the virus, has not yet been authorized in the United States and is currently under U.S. Food and Drug Administration review.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)

[© 2022 Thomson Reuters. All rights reserved.] 

This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.